In the wake of Coherus’ 30% reduction in workforce last week—a move that followed the company’s complete response letter from the FDA regarding its CHS-1701, a pegfilgrastim biosimilar candidate—the California-based biosimilar developer has sustained yet another blow to its business.
In the wake of Coherus’ 30% reduction in workforce last week—a move that followed the company’s complete response letter from the FDA regarding its CHS-1701, a pegfilgrastim biosimilar candidate—the California-based biosimilar developer has sustained yet another blow to its business.
Daiichi Sankyo said in a July 5 press release that it has decided to discontinue its partnership with Coherus BioSciences in the development of CHS-0214, an investigational etanercept biosimilar.
While the Tokyo-based Daiichi Sankyo said that its phase 3 trial for CHS-0214 had met its primary endpoint of determining equivalence between CHS-0214 and its reference product groups, the fact that a commercial manufacturing process to facilitate a supply of the biosimilar product in Japan could not be established had forced the company to sever its ties with Coherus on the product’s development and commercialization.
CHS-0214 was 1 of 2 biosimilars on which Daiichi Sankyo and Coherus had agreed to partner in 2012; the second product, a proposed rituximab biosimilar, appears to be unaffected by the end of the firms’ agreement on the etanercept biosimilar.
The end of the Daiichi Sankyo arrangement is the second such termination for Coherus’ CHS-0214 in the past year; Coherus regained the rights to the biosimilar candidate from Shire after the latter company’s “strategic portfolio review” in 2016.
Of the 3 biosimilar products currently in Coherus’ pipeline, only its adalimumab candidate, CHS-1420, appears to be fully on track; after an initial pharmacokinetic (PK) and bioequivalence (BE) study comparing CHS-1420 to reference adalimumab (Humira) successfully met its endpoints, Coherus initiated a phase 3 study in patients with psoriasis in 2015. Coherus incorporated a switch between the reference and CHS-1420 in the phase 3 study after receiving feedback from the FDA and EMA. The company plans to file a Biologics License Application (BLA) for the product in 2018.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.